Protagenic Therapeutics Announces FDA Pre‑IND Feedback, Targets IND in 2026

What Happened

• On August 20, 2026, Protagenic Therapeutics, Inc. announced it received written responses from the U.S. Food and Drug Administration to its Type B pre‑IND meeting request for PT00114, the company’s lead investigational neuropeptide candidate targeting the TCAP pathway for generalized anxiety disorder (GAD).
• Based on the FDA feedback, the company currently intends to submit an Investigational New Drug (IND) application before the end of 2026 and is targeting first patient dosing in the first half of 2027, each subject to FDA review/clearance and completion of IND‑enabling CMC, manufacturing and nonclinical activities. PT00114 is investigational and not approved by the FDA.

Key Details

• Filing date: August 20, 2026 (Current Report on Form 8‑K).
• Program: PT00114 — targets the teneurin C‑terminal associated peptide (TCAP) pathway for GAD.
• Timing: Company intends to submit IND by end of 2026; targets first patient dosing in H1 2027, contingent on FDA clearance and completion of required work.
• Regulatory note: FDA responses to a Type B pre‑IND meeting are non‑binding; the company disclosed standard forward‑looking statement risks including potential additional FDA requests, clinical holds, need for more capital, and a previously disclosed going concern uncertainty.

Why It Matters

• The FDA feedback and the company’s planned IND timeline are material near‑term development milestones for PT00114. If the IND is accepted and the Phase 1 program proceeds, those steps could de‑risk the program’s regulatory path and create potential value inflection points.
• Investors should note the company’s stated contingencies and risks: the FDA’s advice is non‑binding, additional data or delays are possible, and the company may require substantial additional capital. The filing explicitly contains forward‑looking statements and references risks (including going concern risk) disclosed in the company’s prior SEC reports.